| 1 | ICH Guidelines-Efficacy | E11 Step 4 | CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION | 
		
			| 2 | ICH Guidelines-Efficacy | E10 Step 4 | CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS | 
		
			| 3 | ICH Guidelines-Efficacy | E9 Step 4 | STATISTICAL PRINCIPLES FOR CLINICAL TRIALS | 
		
			| 4 | ICH Guidelines-Efficacy | E8 Step 4 | GENERAL CONSIDERATIONS FOR CLINICAL TRIALS | 
		
			| 5 | ICH Guidelines-Efficacy | E7 Step 4 | STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS | 
		
			| 6 | ICH Guidelines-Efficacy | Questions & Answers | E7 Studies in Support of Special Populations: Geriatrics | 
		
			| 7 | ICH Guidelines-Efficacy | E6(R1) Step 4 | GUIDELINE FOR GOOD CLINICAL PRACTICE | 
		
			| 8 | ICH Guidelines-Efficacy | E5(R1) Step 4 | ETHNIC FACTORS IN THE ACCEPTABILITY OF FOREIGN CLINICAL DATA | 
		
			| 9 | ICH Guidelines-Efficacy | Questions & Answers | E5 Implementation Working Group | 
		
			| 10 | ICH Guidelines-Efficacy | E4 Step 4 | DOSE-RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION | 
		
			| 11 | ICH Guidelines-Efficacy | E3 Step 4 | STRUCTURE AND CONTENT OF CLINICAL STUDY REPORTS | 
		
			| 12 | ICH Guidelines-Efficacy | E2F Step 4 | DEVELOPMENT SAFETY UPDATE REPORT | 
		
			| 13 | ICH Guidelines-Efficacy | CH E2F | EXAMPLE DSUR – PHASE III INVESTIGATIONAL DRUG-MODEL DSUR – Non-Commercial Sponsor-Vasculogenesis Growth Factor-2 (VGF-2)-Development Safety Update Report #2 | 
		
			| 14 | ICH Guidelines-Efficacy | ICH E2F Step 4 | EXAMPLE DSUR – PHASE III INVESTIGATIONAL DRUG ZB3579 | 
		
			| 15 | ICH Guidelines-Efficacy | E2E Step 4 | PHARMACOVIGILANCE PLANNING | 
		
			| 16 | ICH Guidelines-Efficacy | E2D step 4 | POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING | 
		
			| 17 | ICH Guidelines-Efficacy | E2C(R1) Step 4 | CLINICAL SAFETY DATA MANAGEMENT: PERIODIC SAFETY UPDATE REPORTS FOR MARKETED DRUGS | 
		
			| 18 | ICH Guidelines-Efficacy | E2B(R2) Step 4 | MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL SAFETY DATA MANAGEMENT : DATA ELEMENTS FOR TRANSMISSION OF INDIVIDUAL CASE SAFETY REPORTS | 
		
			| 19 | ICH Guidelines-Efficacy | E2A Step 4 | CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING | 
		
			| 20 | ICH Guidelines-Efficacy | E1 Step 4 | THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL SAFETY FOR DRUGS INTENDED FOR LONG-TERM TREATMENT OF NON-LIFE-THREATENING CONDITIONS |